Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (10): 997-1003.DOI: 10.3969/j.issn.1673-8640.2026.10.010
Previous Articles Next Articles
HUANG Zhixi, GUO Ping, WANG Jianbiao, YANG Mingkang, HUA Renxiang, ZHOU Jiakuan, XUE Yilun, CAI Qi(
)
Received:2025-11-27
Revised:2026-03-13
Online:2026-10-30
Published:2026-10-20
CLC Number:
HUANG Zhixi, GUO Ping, WANG Jianbiao, YANG Mingkang, HUA Renxiang, ZHOU Jiakuan, XUE Yilun, CAI Qi. Genetic analysis and literature review of neutral lipid storage disease with myopathy with Jordan's anomaly[J]. Laboratory Medicine, 2026, 41(10): 997-1003.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.10.010
| 序号 | 基因 | 突变类型 | 位点 | 致病性预测(ClinVar) | 引用文献 |
|---|---|---|---|---|---|
| 1 | PNPLA2 | 复合杂合 | c.24G>A;c.798dupC | 可能致病 | [ |
| 2 | PNPLA2 | 复合杂合 | c.919delG;c.757+1G > T | [ | |
| 3 | PNPLA2;CLCN1 | PNPLA2:c.792del;CLCN1:c.1453A>G | 致病/可能致病 | [ | |
| 4 | PNPLA2 | 纯和 | c.40 G>A | 意义未明 | [ |
| 5 | GNE;PNPLA2 | GNE杂合;PNPLA2纯和 | GNE:c.2179G>T;PNPLA2:c.662G>C | 致病 | [ |
| 6 | PNPLA2 | 纯合 | c.194delC | [ | |
| 7 | PNPLA2 | 纯合 | c.757+1G>T | 致病 | [ |
| 8 | PNPLA2 | 复合杂合 | c.167T>G;c.577A>T | [ | |
| 9 | PNPLA2 | 纯和 | c.557C > G | [ | |
| 10 | PNPLA2 | 纯合 | c.155C > G | [ | |
| 11 | PNPLA2 | 纯合 | c.757+1G > T | 致病 | [ |
| 12 | PNPLA2 | 复合杂合 | c.696+4A>G;c.553_565delGTCCCCCTTCTCG | [ | |
| 13 | PNPLA2;ACADSB | 纯和;纯和 | c.757+1 G >T;c.1165A > G | [ | |
| 14 | PNPLA2 | 纯和 | c.497 A>G | 致病性分类存在冲突 | [ |
| 15 | PNPLA2 | 纯和 | c.714C>A | [ | |
| 16 | PNPLA2 | 纯和 | c.187+1G>A | 致病/可能致病 | [ |
| 17 | PNPLA2 | 纯和 | c.187+1G>A | 致病/可能致病 | |
| 18 | PNPLA2 | 纯和 | c.576delC | [ | |
| 19 | PNPLA2 | 纯和 | c.1081G>T | [ | |
| 20 | PNPLA2 | 纯和 | c.865C>T | 致病 | [ |
| 21 | PNPLA2 | 纯和 | c.263+1G>A | [ | |
| 22 | PNPLA2 | 纯和 | c.263+1G>A | ||
| 23 | PNPLA2 | c.553T>C | 意义未明 | [ | |
| 24 | PNPLA2 | 纯和 | c.757+1G>T | 致病 | [ |
| 25 | PNPLA2 | 纯和 | c.757+1G>T | 致病 | |
| 26 | PNPLA2 | c.750_757del | [ |
| 序号 | 基因 | 突变类型 | 位点 | 致病性预测(ClinVar) | 引用文献 |
|---|---|---|---|---|---|
| 1 | PNPLA2 | 复合杂合 | c.24G>A;c.798dupC | 可能致病 | [ |
| 2 | PNPLA2 | 复合杂合 | c.919delG;c.757+1G > T | [ | |
| 3 | PNPLA2;CLCN1 | PNPLA2:c.792del;CLCN1:c.1453A>G | 致病/可能致病 | [ | |
| 4 | PNPLA2 | 纯和 | c.40 G>A | 意义未明 | [ |
| 5 | GNE;PNPLA2 | GNE杂合;PNPLA2纯和 | GNE:c.2179G>T;PNPLA2:c.662G>C | 致病 | [ |
| 6 | PNPLA2 | 纯合 | c.194delC | [ | |
| 7 | PNPLA2 | 纯合 | c.757+1G>T | 致病 | [ |
| 8 | PNPLA2 | 复合杂合 | c.167T>G;c.577A>T | [ | |
| 9 | PNPLA2 | 纯和 | c.557C > G | [ | |
| 10 | PNPLA2 | 纯合 | c.155C > G | [ | |
| 11 | PNPLA2 | 纯合 | c.757+1G > T | 致病 | [ |
| 12 | PNPLA2 | 复合杂合 | c.696+4A>G;c.553_565delGTCCCCCTTCTCG | [ | |
| 13 | PNPLA2;ACADSB | 纯和;纯和 | c.757+1 G >T;c.1165A > G | [ | |
| 14 | PNPLA2 | 纯和 | c.497 A>G | 致病性分类存在冲突 | [ |
| 15 | PNPLA2 | 纯和 | c.714C>A | [ | |
| 16 | PNPLA2 | 纯和 | c.187+1G>A | 致病/可能致病 | [ |
| 17 | PNPLA2 | 纯和 | c.187+1G>A | 致病/可能致病 | |
| 18 | PNPLA2 | 纯和 | c.576delC | [ | |
| 19 | PNPLA2 | 纯和 | c.1081G>T | [ | |
| 20 | PNPLA2 | 纯和 | c.865C>T | 致病 | [ |
| 21 | PNPLA2 | 纯和 | c.263+1G>A | [ | |
| 22 | PNPLA2 | 纯和 | c.263+1G>A | ||
| 23 | PNPLA2 | c.553T>C | 意义未明 | [ | |
| 24 | PNPLA2 | 纯和 | c.757+1G>T | 致病 | [ |
| 25 | PNPLA2 | 纯和 | c.757+1G>T | 致病 | |
| 26 | PNPLA2 | c.750_757del | [ |
| [1] | 中华医学会神经病学分会, 中华医学会神经病学分会神经肌肉病学组, 中华医学会神经病学分会肌电图及临床神经生理学组. 中国脂质沉积性肌病诊治专家共识[J]. 中华神经科杂志, 2015, 48(11):941-945. |
| [2] | Şenol H B, Kısa P T, Kulu B, et al. A novel PNPLA2 variant in a female patient with neutral lipid storage disease with myopathy and hypogonadotropic hypogonadism[J]. Mol Syndromol, 2025, 16(1):93-98. |
| [3] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
DOI PMID |
| [4] |
Yang T, Zhu J, Kang Y, et al. Two PNPLA2 heterozygous mutations result in neutral lipid storage disease with myopathy:a case report[J]. BMC Musculoskelet Disord, 2024, 25(1):661.
DOI |
| [5] |
Missaglia S, Maggi L, Mora M, et al. Late onset of neutral lipid storage disease due to novel PNPLA2 mutations causing total loss of lipase activity in a patient with myopathy and slight cardiac involvement[J]. Neuromuscul Disord, 2017, 27(5):481-486.
DOI URL |
| [6] |
Landim J I D, Ribeiro I S, Oliveira E B, et al. Neutral lipid storage disease with myopathy and myotonia associated to pathogenic variants on PNPLA2 and CLCN1 genes:case report[J]. BMC Neurol, 2023, 23(1):171.
DOI |
| [7] |
Yamada K, Yaguchi H, Abe M, et al. Neutral lipid storage disease with myopathy with a novel homozygous PNPLA2 variant[J]. Clin Neurol Neurosurg, 2023, 228:107670.
DOI URL |
| [8] |
Zuccarino R, Anderson D M, Holman C, et al. Neutral lipid-storage disease with myopathy and Jordan anomaly[J]. Neurology, 2020, 95(13):599-600.
DOI PMID |
| [9] |
Samukawa M, Nakamura N, Hirano M, et al. Neutral lipid storage disease associated with the PNPLA2 gene:case report and literature review[J]. Eur Neurol, 2020, 83(3):317-322.
DOI PMID |
| [10] | Zhang J, Han J, Wang Y, et al. Neutral lipid storage disease with myopathy presenting asymmetrical muscle weakness:a case report[J]. Int J Clin Exp Pathol, 2020, 13(3):559-562. |
| [11] |
Pegoraro V, Missaglia S, Marozzo R, et al. MiRNAs as biomarkers of phenotype in neutral lipid storage disease with myopathy[J]. Muscle Nerve, 2020, 61(2):253-257.
DOI PMID |
| [12] |
Garcia M A, Rojas J A, Millán S P, et al. Neutral lipid storage disease with myopathy and dropped head syndrome. Report of a new variant susceptible of treatment with late diagnosis[J]. J Clin Neurosci, 2018, 58:207-209.
DOI PMID |
| [13] |
Zheng S, Liao W. Novel PNPLA2 gene mutation in a child causing neutral lipid storage disease with myopathy[J]. BMC Med Genet, 2018, 19(1):172.
DOI |
| [14] |
Latimer C S, Schleit J, Reynolds A, et al. Neutral lipid storage disease with myopathy:further phenotypic characterization of a rare PNPLA2 variant[J]. Neuromuscul Disord, 2018, 28(7):606-609.
DOI URL |
| [15] | Foster L A, Courville E L, Manousakis G. Clinical reasoning:a 33-year-old man with cardiomyopathy and myopathy[J]. Neurology, 2016, 87(8):e74-e78. |
| [16] |
Muggenthaler M, Petropoulou E, Omer S, et al. Whole exome sequence analysis reveals a homozygous mutation in PNPLA2 as the cause of severe dilated cardiomyopathy secondary to neutral lipid storage disease[J]. Int J Cardiol, 2016, 210:41-44.
DOI PMID |
| [17] |
Massa R, Pozzessere S, Rastelli E, et al. Neutral lipid-storage disease with myopathy and extended phenotype with novel PNPLA2 mutation[J]. Muscle Nerve, 2016, 53(4):644-648.
DOI URL |
| [18] |
Xu C, Zhao Y, Liu J, et al. Muscle MRI in neutral lipid storage disease with myopathy carrying mutation c.187+1G>A[J]. Muscle Nerve, 2015, 51(6):922-927.
DOI URL |
| [19] |
Kaneko K, Kuroda H, Izumi R, et al. A novel mutation in PNPLA2 causes neutral lipid storage disease with myopathy and triglyceride deposit cardiomyovasculopathy:a case report and literature review[J]. Neuromuscul Disord, 2014, 24(7):634-641.
DOI URL |
| [20] |
Shahriyari H, Ramezani M, Nilipour Y, et al. Neutral lipid storage disease with myopathy:clinicopathological and genetic features of nine Iranian patients[J]. Neuromuscul Disord, 2024, 35:19-24.
DOI URL |
| [21] |
Ash D B, Papadimitriou D, Hays A P, et al. A novel mutation in PNPLA2 leading to neutral lipid storage disease with myopathy[J]. Arch Neurol, 2012, 69(9):1190-1192.
DOI URL |
| [22] | Laforêt P, Ørngreen M, Preisler N, et al. Blocked muscle fat oxidation during exercise in neutral lipid storage disease[J]. Arch Neurol, 2012, 69(4):530-533. |
| [23] |
Chen J, Hong D, Wang Z, et al. A novel PNPLA2 mutation causes neutral lipid storage disease with myopathy(NLSDM)presenting muscular dystrophic features with lipid storage and rimmed vacuoles[J]. Clin Neuropathol, 2010, 29(6):351-356.
PMID |
| [24] |
邢莹, 普程伟, 尚柯, 等. 中性脂肪沉积症伴肌病患者的外周血细胞形态特点并文献复习[J]. 中国全科医学, 2022, 25(24):3065-3069.
DOI |
| [25] | 卢晓庆, 胡波琳, 陈燕红, 等. PNPLA2基因新发纯合移码突变导致中性脂肪沉积症伴肌病1例报告[J]. 中风与神经疾病杂志, 2018, 35(10):935-936. |
| [26] |
Wang S, Wu S, Peng D. Dilated cardiomyopathy caused by mutation of the PNPLA2 gene:a case report and literature review[J]. Front Genet, 2024, 15:1415156.
DOI URL |
| [27] |
Avila-smirnow D, Durán-saavedra G, Ovalle-besa P, et al. Early onset neutral lipid storage disease with myopathy presenting as congenital hypotonia and hepatomegaly[J]. Neuromuscul Disord, 2021, 31(1):52-55.
DOI URL |
| [28] |
Pennisi E M, Missaglia S, Dimauro S, et al. A myopathy with unusual features caused by PNPLA2 gene mutations[J]. Muscle Nerve, 2015, 51(4):609-613.
DOI PMID |
| [29] | Van De Weijer T, Havekes B, Bilet L, et al. Effects of bezafibrate treatment in a patient and a carrier with mutations in the PNPLA2 gene,causing neutral lipid storage disease with myopathy[J]. Circ Res, 2013, 112(5):e51-e54. |
| [30] |
Luan Y N, Shi G Z, Li Q X, et al. Clinicopathological-genetic features of neutral lipid storage disease with myopathy from a Chinese neuromuscular center[J]. Orphanet J Rare Dis, 2025, 20(1):322.
DOI |
| [31] |
Missaglia S, Coleman R A, Mordente A, et al. Neutral lipid storage diseases as cellular model to study lipid droplet function[J]. Cells, 2019, 8(2):187.
DOI URL |
| [32] | Kintscher U, Foryst-ludwig A, Haemmerle G, et al. The role of adipose triglyceride lipase and cytosolic lipolysis in cardiac function and heart failure[J]. Cell Rep Med, 2020, 1(1):100001. |
| [33] |
Tan J, Yang H, Fan J, et al. Patients with neutral lipid storage disease with myopathy(NLSDM)in Southwestern China[J]. Clin Neurol Neurosurg, 2018, 168:102-107.
DOI URL |
| [34] | Chanarin I, Patel A, Slavin G, et al. Neutral-lipid storage disease:a new disorder of lipid metabolism[J]. Br Med J, 1975, 1(5957):553-555. |
| [35] |
Kobayashi K, Inoguchi T, Maeda Y, et al. The lack of the C-terminal domain of adipose triglyceride lipase causes neutral lipid storage disease through impaired interactions with lipid droplets[J]. J Clin Endocrinol Metab, 2008, 93(7):2877-2884.
DOI URL |
| [36] |
Li X, Chen J, Li J, et al. ATGL regulates renal fibrosis by reprogramming lipid metabolism during the transition from AKI to CKD[J]. Mol Ther, 2025, 33(2):805-822.
DOI PMID |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||